Obagi Medical Products, Inc. (NASDAQ:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that Preston Romm, the Company's Chief Financial Officer and EVP, Finance, Operations and Administration will present a corporate overview at the following two investor conferences:

  • Piper Jaffray's 23rd Annual Health Care Conference to be held at The New York Palace Hotel in New York. The presentation will take place at 4:30pm (EST) on Tuesday, November 29th.
  • Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference to be held at The St. Regis Hotel in San Francisco. The presentation will take place at 2:20pm (PST) on Tuesday, December 6th.

A live webcast of the presentations will be available via the internet by visiting the Investor Relations section of the Company's web site at www.obagi.com. The archived presentation will be available on the web site for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics? technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical's portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash?® Eyelash Solution, Obagi Blue Peel RADIANCETM, and Nu-Derm® Sun Shield ? SPF 50. Visit www.obagi.com for information.

Obagi Medical Products, Inc.
Preston Romm
CFO, EVP of Finance, Operations and Administration
562-628-1007